Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research DZL, Heidelberg, Germany.
Department of Medicine-2 (Oncology, Gastroenterology, Pulmonology, and Infectious Diseases), and University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, HepatologyLeipzig, Germany.
Support Care Cancer. 2022 Apr;30(4):3131-3140. doi: 10.1007/s00520-021-06736-2. Epub 2021 Dec 7.
The purpose of this study is to investigate changes over time in quality of life (QoL) in incurable lung cancer patients and the impact of determinants like molecular alterations (MA).
In a prospective, longitudinal, multicentric study, we assessed QoL, symptom burden, psychological distress, unmet needs, and prognostic understanding of patients diagnosed with incurable lung cancer at the time of the diagnosis (T0) and after 3 (T1), 6 (T2) and 12 months (T3) using validated questionnaires like FACT-L, National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT), PHQ-4, SCNS-SF-34, and SEIQoL.
Two hundred seventeen patients were enrolled, 22 (10%) with reported MA. QoL scores improved over time, with a significant trend for DT, PHQ-4, and SCNS-SF-34. Significant determinants for stable or improving scores over time were survival > 6 months, performance status at the time of diagnosis, and presence of MA. Patients with MA showed better QoL scores (FACT-L at T1 104.4 vs 86.3; at T2 107.5 vs 90.0; at T3 100.9 vs 92.8) and lower psychological distress (NCCN DT at T1 3.3 vs 5; at T2 2.7 vs 4.5; at T3 3.7 vs 4.5; PHQ-4 at T1 2.3 vs 4.1; at T2 1.7 vs 3.6; at T3 2.2 vs 3.6), but also a worsening of the scores at 1 year and a higher percentage of inaccurate prognostic understanding (27 vs 17%) compared to patients without MA.
Patients with tumors harboring MA are at risk of QoL deterioration during the course of the disease. Physicians should adapt their communication strategies in order to maintain or improve QoL.
本研究旨在探讨不可治愈的肺癌患者生活质量(QoL)随时间的变化,以及分子改变(MA)等决定因素的影响。
在一项前瞻性、纵向、多中心研究中,我们使用经过验证的问卷(如 FACT-L、国家综合癌症网络(NCCN)痛苦温度计(DT)、PHQ-4、SCNS-SF-34 和 SEIQoL)评估了在诊断时(T0)以及诊断后 3(T1)、6(T2)和 12 个月(T3)时被诊断为不可治愈的肺癌患者的 QoL、症状负担、心理困扰、未满足的需求和预后理解。
共纳入 217 例患者,其中 22 例(10%)报告存在 MA。QoL 评分随时间推移而改善,DT、PHQ-4 和 SCNS-SF-34 评分呈显著趋势。生存时间超过 6 个月、诊断时的体能状态和 MA 的存在是评分随时间稳定或改善的显著决定因素。存在 MA 的患者 QoL 评分更高(T1 时 FACT-L 为 104.4 分比 86.3 分;T2 时为 107.5 分比 90.0 分;T3 时为 100.9 分比 92.8 分),心理困扰较低(T1 时 NCCN DT 为 3.3 分比 5 分;T2 时为 2.7 分比 4.5 分;T3 时为 3.7 分比 4.5 分;PHQ-4 时为 2.3 分比 4.1 分;T2 时为 1.7 分比 3.6 分;T3 时为 2.2 分比 3.6 分),但 1 年后评分恶化,对预后的不准确理解比例更高(27%比 17%)。
携带 MA 的肿瘤患者在疾病过程中存在 QoL 恶化的风险。医生应调整沟通策略,以维持或提高 QoL。